ReviewBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2015
Classical and recent advances in the treatment of inflammatory bowel diseases.
Review in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.
- Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease.The Cochrane database of systematic reviews · 2020Pooled it
- Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age.Advances in therapy · 2017Trial
- Pimenta racemosa extract ameliorates chemically induced ulcerative colitis in rats by suppressing inflammation and oxidative stress.Inflammopharmacology · 2026Article
- Ethanolic Extract of Kinkeliba (International journal of molecular sciences · 2025Article
- α-Bisabolol, a Dietary Bioactive Terpene Attenuates Oxidative Stress and Inflammation in Colonic Mucosa of Acetic Acid-Induced Colitis in Rats.International journal of molecular sciences · 2025Article
- Phenolic Profiling and Bioactive Properties ofInternational journal of molecular sciences · 2025Article
- Molecular Impact of Magnesium-Mediated Immune Regulation in Diseases.Scientifica · 2025Review
- Saffron as a Promising Therapy for Inflammatory Bowel Disease.Nutrients · 2024Review
- Therapeutic Benefits of Tuna Oil by In Vitro and In Vivo Studies Using a Rat Model of Acetic Acid-Induced Ulcerative Colitis.Applied biochemistry and biotechnology · 2024Article
- Inhibition of TLR4, NF-κB, and INOS pathways mediates ameliorative effect of syringic acid in experimental ulcerative colitis in rats.Inflammopharmacology · 2024Article
- Effects of Mimosa caesalpiniifolia pre-formulation on the intestinal barrier during sodium dextran sulfate-induced colitis in Wistar ratsBiomedica : revista del Instituto Nacional de Salud · 2023Article
- Article
- Coumaric acid ameliorates experimental colitis in rats through attenuation of oxidative stress, inflammatory response and apoptosis.Inflammopharmacology · 2022Article
- Berberine and its derivatives represent as the promising therapeutic agents for inflammatory disorders.Pharmacological reports : PR · 2022Review
- Article
- Identification of a Disease-Associated Network of Intestinal Immune Cells in Treatment-Naive Inflammatory Bowel Disease.Frontiers in immunology · 2022Article
- The Role of Tissue-Resident Macrophages in the Development and Treatment of Inflammatory Bowel Disease.Frontiers in cell and developmental biology · 2022Review
- The role ofFrontiers in immunology · 2022Review
- Anethole Ameliorates Acetic Acid-Induced Colitis in Mice: Anti-Inflammatory and Antioxidant Effects.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Methotrexate showed efficacy both in Crohn's disease and ulcerative colitis, predictors of surgery were identified in patients initially treated with methotrexate monotherapy.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease (CD) and ulcerative colitis (UC) are intestinal disorders that comprise the inflammatory bowel diseases (IBD). These disorders have a significant effect on the quality of life of affected patients and the increasing number of IBD cases worldwide is a growing concern. Because of the overall burden of IBD and its multifactorial etiology, efforts have been made to improve the medical management of these inflammatory conditions. The classical therapeutic strategies aim to control the exacerbated host immune response with aminosalicylates, antibiotics, corticosteroids, thiopurines, methotrexate and anti-tumor necrosis factor (TNF) biological agents. Although successful in the treatment of several CD or UC conditions, these drugs have limited effectiveness, and variable responses may culminate in unpredictable outcomes. The ideal therapy should reduce inflammation without inducing immunosuppression, and remains a challenge to health care personnel. Recently, a number of additional approaches to IBD therapy, such as new target molecules for biological agents and cellular therapy, have shown promising results. A deeper understanding of IBD pathogenesis and the availability of novel therapies are needed to improve therapeutic success. This review describes the overall key features of therapies currently employed in clinical practice as well as novel and future alternative IBD treatment methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.